Limitations of Human Tumour Xenografts in Drug Testing
Author Information
Author(s): M.J. Bailey, A.J. Jones, A.J. Shorthouse, D. Raghaven, P. Selby, J. Gibbs, M.J. Peckham
Primary Institution: Institute of Cancer Research
Hypothesis
Can human tumour xenografts be effectively used for individual patient drug sensitivity testing?
Conclusion
The study concludes that the use of human tumour xenografts for individual patient drug sensitivity testing is limited due to low take rates and long delays in obtaining results.
Supporting Evidence
- 75 serially transplantable xenograft lines were established from 239 implanted specimens.
- Only 10% of patients could have had chemosensitivity testing performed before their death.
- The overall take rate for xenografts was 31%, with significant variation by tumour type.
Takeaway
This study looked at whether we can use human tumour samples grown in mice to test how well different cancer drugs work for individual patients, but it found that this method isn't very helpful.
Methodology
The study involved implanting human tumour specimens into immunosuppressed mice and assessing the establishment of xenograft lines and their potential for drug sensitivity testing.
Potential Biases
Patients with advanced disease were excluded from the analysis to avoid bias, but this may have limited the applicability of the findings.
Limitations
Only a small percentage of patients had xenograft lines established that could yield useful drug sensitivity data before their death.
Participant Demographics
Patients included those with various tumour types, with some having received prior radiotherapy.
Want to read the original?
Access the complete publication on the publisher's website